AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..
HQ Team February 8, 2024: Australian scientists may have found a drug to treat triple-negative breast cancer without any toxic effects, according to.
More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according.
HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..
HQ Team December 12, 2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese.
HQ Team October 30, 2023: Researchers have unraveled a critical mechanism involving the dynein protein, shedding light on how it aids the spread.
HQ Team October 5, 2023: A new study by Columbia University Mailman School of Public Health and NYU Grossman School of Medicine says.
HQ Team August 30, 2023: Roche’s atezolizumab drug Tecentriq, to treat cancer, was approved by Britain’s Medicines and Healthcare Products Regulatory Agency. Tecentriq.
HQ Team July 29, 2023: Merck & Co., Inc., announced it has met one of the primary goals during a late-stage trial of.